menu
    • menu

    Company profile for Allyx Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Allyx Therapeutics is focused on introducing a novel approach to preserve and protect synapses for individuals with neurodegenerative diseases. Their lead compound, ALX-001, represents a first-in-class oral therapy with a distinctive mechanism of action targeting mGluR5. Clinical programs, particularly in Alzheimer's disease (Phase 1b), are actively progressing. Founded in 2019 by a team of Yale scientists, experienced biophar...
    Allyx Therapeutics is focused on introducing a novel approach to preserve and protect synapses for individuals with neurodegenerative diseases. Their lead compound, ALX-001, represents a first-in-class oral therapy with a distinctive mechanism of action targeting mGluR5. Clinical programs, particularly in Alzheimer's disease (Phase 1b), are actively progressing. Founded in 2019 by a team of Yale scientists, experienced biopharma industry professionals, and venture capitalists, Allyx has secured funding from various sources, including non-dilutive support from the National Institutes of Health (NIH).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Allyx TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    555 Long Wharf Drive Floor 11 New Haven, CT 06511
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://allyxthera.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/allyx-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/allyxthera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allyx Therapeutics Awarded $3.3 Million NIH Grant For ALX-001
    Allyx Therapeutics Awarded $3.3 Million NIH Grant For ALX-001

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2963064/0/en/Allyx-Therapeutics-Awarded-3-3-Million-NIH-Grant-to-Support-Further-Clinical-Studies-of-Lead-Candidate-ALX-001.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    Allyx Treats First Parkinson's Patient With ALX-001
    Allyx Treats First Parkinson's Patient With ALX-001

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940463/0/en/Allyx-Therapeutics-Announces-First-Parkinson-s-Disease-Patient-Treated-with-ALX-001.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated ALX-001
    Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated ALX-001

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896705/0/en/Allyx-Therapeutics-Announces-First-Alzheimer-s-Disease-Patient-Treated-with-Lead-Compound-ALX-001.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share
    Allyx Announces Positive Phase 1b Data and Advances ALX-001
    Allyx Announces Positive Phase 1b Data and Advances ALX-001

    11 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/11/2843754/0/en/Allyx-Therapeutics-Announces-Positive-Phase-1b-Multiple-Ascending-Dose-Data-and-Advances-ALX-001-to-Patients.html

    GLOBENEWSWIRE
    11 Mar 2024
    Share Share
    Allyx Announces Expansion into Parkinsons Disease Clinical Research
    Allyx Announces Expansion into Parkinsons Disease Clinical Research

    05 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/05/2840394/0/en/Allyx-Therapeutics-Announces-Expansion-into-Parkinson-s-Disease-Clinical-Research-with-Lead-Compound-ALX-001-Following-IND-Acceptance.html

    GLOBENEWSWIRE
    05 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search